Tonix Pharmaceuticals Presents Results of TNX-102 SL in P-III RELIEF study for the Management of Fibromyalgia at ASCP 2021

June 4, 2021 Auto Bot Clinical Trials, P-III 0

Shots:

  • The P-III RELIEF study evaluating the efficacy and safety of TNX-102 SL (cyclobenzaprine HCl sublingual tablets) vs PBO in patients for the management of fibromyalgia. The first 2 wks treatment start on TNX-102 SL (2.8 mg) or PBO and after that the dose increased to TNX-102 SL (5.6 mg) or 2 PBO for 12 wks
  • The trial met its 1EPs i.e TNX-102 SL (5mg) showed a reduction in daily pain with a higher rate of ≥30% pain responders. The 2EPs include improvements in sleep quality, mitigation of fatigue, and fibromyalgia-specific functional recovery, and were well tolerated
  • The interim analysis results for the P-III RALLY study is expected in Q3’21

Click here to­ read full press release/ article | Ref: Globe Newswire | Image: Trading View

The post Tonix Pharmaceuticals Presents Results of TNX-102 SL in P-III RELIEF study for the Management of Fibromyalgia at ASCP 2021 first appeared on PharmaShots.